China and the U.S. are enacting policies that could stymie biomedical innovation
An overview of U.S. and China policies that could hurt both investment and innovaton in biotech
Amidst rising tensions between the U.S. and China, both governments have enacted policies in recent years that could hinder innovation and hurt public health over the long term.
Protectionist mindsets, coupled with concerns about industrial espionage and IP theft, have led both countries to erect barriers that will limit foreign access to their respective biopharma sectors.
Many of the policies mirror each other.
The escalation is not a direct tit-for-tat exchange, but the result of parallel processes that cover investments